Alkermes Plc EPS Soars Past Forecasts
Alkermes reported strong earnings by exceeding both revenue and earnings expectations in its latest quarterly release.
Alkermes (NASDAQ:ALKS), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported robust financial results, beating analyst estimates with a non-GAAP EPS of $1.04 against an expected $0.76. Revenue also exceeded projections, reaching $430 million compared to the $379 million forecast.
Overall, the company delivered a strong quarter, driven by significant sales from its proprietary product portfolio, although challenges in manufacturing and royalties remain.
Source: Alkermes. Analyst estimates for the quarter provided by FactSet.
